Profile data is unavailable for this security.
About the company
Soleno Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of rare diseases. The Company’s lead product candidate, diazoxide choline extended-release tablets (DCCR), is for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. DCCR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. Its proposed mode of action, with targets in the brain, pancreas and fat tissue, has the potential to broadly impact complex diseases like PWS to reduce appetite, reduce food-seeking, decrease insulin and leptin resistance, and reduce body fat. The Company has Breakthrough Therapy and Fast-Track designations in the United States and Orphan Drug designations in the United States and European Union.
- Revenue in USD (TTM)98.68m
- Net income in USD-78.45m
- Incorporated1999
- Employees152.00
- LocationSoleno Therapeutics Inc100 Marine Parkway, Suite 400REDWOOD CITY 94065United StatesUSA
- Phone+1 (302) 658-7581
- Fax+1 (302) 655-5049
- Websitehttps://soleno.life/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MannKind Corp | 313.79m | 28.76m | 1.76bn | 407.00 | 61.98 | -- | 47.42 | 5.62 | 0.0926 | 0.0926 | 1.02 | -0.1451 | 0.6545 | 2.52 | 17.64 | 770,975.40 | 6.00 | -14.54 | 7.40 | -19.49 | 78.49 | 65.89 | 9.16 | -28.96 | 3.04 | 2.68 | 1.14 | -- | 43.50 | 35.27 | 331.09 | -- | 30.46 | -- |
| Ardelyx Inc | 398.23m | -56.55m | 1.76bn | 395.00 | -- | 11.43 | -- | 4.43 | -0.2364 | -0.2364 | 1.66 | 0.635 | 0.9326 | 2.57 | 6.14 | 1,008,187.00 | -13.24 | -35.80 | -16.15 | -45.22 | 88.21 | 86.06 | -14.20 | -80.49 | 4.11 | -2.07 | 0.5671 | -- | 168.06 | 129.14 | 40.76 | -- | 25.48 | -- |
| Semnur Pharmaceuticals Inc | 0.00 | -1.46m | 1.84bn | -- | -- | -- | -- | -- | -0.4678 | -0.4678 | 0.00 | -4.05 | 0.00 | -- | -- | -- | -5.54 | -- | -7.67 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -126.45 | -- | -- | -- |
| Stoke Therapeutics Inc | 205.63m | 40.57m | 1.84bn | 128.00 | 48.82 | 5.76 | 43.34 | 8.95 | 0.66 | 0.66 | 3.52 | 5.59 | 0.6293 | -- | 35.68 | 1,606,500.00 | 12.41 | -34.04 | 14.44 | -37.36 | -- | -- | 19.73 | -749.56 | -- | -- | 0.00 | -- | 316.34 | -- | 15.01 | -- | -34.11 | -- |
| Olema Pharmaceuticals Inc | 0.00 | -149.96m | 1.86bn | 122.00 | -- | 5.28 | -- | -- | -1.81 | -1.81 | 0.00 | 4.48 | 0.00 | -- | -- | 0.00 | -51.48 | -31.26 | -58.78 | -33.05 | -- | -- | -- | -- | -- | -- | 0.0097 | -- | -- | -- | -33.95 | -- | -- | -- |
| Syndax Pharmaceuticals Inc | 111.55m | -311.58m | 1.89bn | 270.00 | -- | 16.35 | -- | 16.92 | -3.61 | -3.61 | 1.29 | 1.33 | 0.2282 | -- | 4.67 | 413,151.80 | -63.74 | -32.19 | -77.50 | -35.11 | 95.44 | -- | -279.31 | -440.06 | 4.42 | -87.92 | 0.7487 | -- | -- | 73.25 | -52.25 | -- | -- | -- |
| Recursion Pharmaceuticals Inc | 43.69m | -715.54m | 1.93bn | 840.00 | -- | 1.74 | -- | 44.14 | -1.81 | -1.81 | 0.109 | 2.13 | 0.0411 | -- | 3.62 | 52,010.71 | -67.31 | -42.93 | -76.86 | -48.71 | -59.01 | -- | -1,637.81 | -828.92 | -- | -- | 0.0195 | -- | 32.00 | 90.93 | -41.33 | -- | 28.49 | -- |
| Nuvation Bio Inc | 26.75m | -217.48m | 1.96bn | 291.00 | -- | 6.02 | -- | 73.31 | -0.6399 | -0.6399 | 0.0787 | 0.9508 | 0.0456 | -- | 6.34 | 121,581.80 | -37.08 | -33.42 | -41.58 | -34.49 | 54.26 | -- | -813.07 | -11,132.31 | 8.39 | -- | 0.3842 | -- | -- | -- | -649.24 | -- | -24.47 | -- |
| Dianthus Therapeutics Inc | 3.08m | -126.35m | 2.14bn | 78.00 | -- | 3.91 | -- | 695.38 | -3.48 | -3.48 | 0.085 | 12.75 | 0.0066 | -- | 0.8013 | 39,461.54 | -27.12 | -37.13 | -28.32 | -39.78 | -- | -- | -4,104.78 | -3,874.39 | -- | -- | 0.00 | -- | 120.63 | -- | -95.08 | -- | -49.06 | -- |
| Soleno Therapeutics Inc | 98.68m | -78.45m | 2.15bn | 152.00 | -- | 4.35 | -- | 21.80 | -1.84 | -1.84 | 2.02 | 9.21 | 0.2201 | -- | -- | 1,072,554.00 | -17.50 | -59.81 | -18.49 | -66.17 | 98.14 | -- | -79.50 | -- | 15.88 | -- | 0.0915 | -- | -- | -- | -351.04 | -- | 59.68 | -- |
| Maze Therapeutics Inc | 0.00 | -101.46m | 2.27bn | 125.00 | -- | 5.98 | -- | -- | -2.68 | -2.68 | 0.00 | 7.89 | 0.00 | -- | -- | 0.00 | -41.05 | -- | -43.88 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 103.39 | -- | -- | -- |
| Mineralys Therapeutics Inc | 0.00 | -171.36m | 2.36bn | 51.00 | -- | 4.08 | -- | -- | -2.96 | -2.96 | 0.00 | 7.30 | 0.00 | -- | -- | 0.00 | -39.48 | -- | -42.14 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -147.31 | -- | -- | -- |
| Adaptive Biotechnologies Corp | 276.98m | -59.50m | 2.40bn | 619.00 | -- | 10.98 | -- | 8.67 | -0.3987 | -0.3987 | 1.79 | 1.42 | 0.5265 | 7.82 | 6.01 | -- | -11.30 | -22.45 | -13.86 | -25.94 | 74.24 | 66.23 | -21.47 | -88.21 | 3.23 | -24.47 | 0.3684 | -- | 54.77 | 23.00 | 62.69 | -- | -- | -- |
| Wave Life Sciences Ltd | 109.23m | -121.95m | 2.42bn | 287.00 | -- | 17.08 | -- | 22.20 | -0.7363 | -0.7363 | 0.6661 | 0.8262 | 0.3642 | -- | 21.85 | 380,592.30 | -40.66 | -48.01 | -71.05 | -88.09 | -- | -- | -111.64 | -205.56 | -- | -- | 0.00 | -- | -4.42 | 46.62 | -68.67 | -- | -24.87 | -- |
Data as of Feb 11 2026. Currency figures normalised to Soleno Therapeutics Inc's reporting currency: US Dollar USD
59.98%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 6.53m | 12.28% |
| Janus Henderson Investors US LLCas of 30 Sep 2025 | 5.97m | 11.24% |
| T. Rowe Price Associates, Inc. (IM)as of 30 Sep 2025 | 3.85m | 7.24% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 2.94m | 5.53% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 2.66m | 5.01% |
| Avoro Capital Advisor LLCas of 30 Sep 2025 | 2.58m | 4.85% |
| Wellington Management Co. LLPas of 30 Sep 2025 | 2.23m | 4.20% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 2.17m | 4.09% |
| FIAM LLCas of 30 Sep 2025 | 1.47m | 2.77% |
| Invesco Advisers, Inc.as of 30 Sep 2025 | 1.47m | 2.77% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
